Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.

[1]  B. Bonavida,et al.  The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. , 2009, Critical reviews in immunology.

[2]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[3]  D. Peeper,et al.  Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network , 2008, Cell.

[4]  N. Barker,et al.  The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression , 2008, Clinical & Experimental Metastasis.

[5]  D. Bernard,et al.  Involvement of Rel/Nuclear Factor-κB Transcription Factors in Keratinocyte Senescence , 2004, Cancer Research.

[6]  B. Teicher,et al.  Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[8]  R. Hansen,et al.  Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. , 2002, Journal of the National Cancer Institute.

[9]  W. Ellis,et al.  Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer , 2004, Clinical Cancer Research.

[10]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[11]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[12]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[13]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[14]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[15]  Jonathan Melamed,et al.  Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence , 2008, Cell.

[16]  R. Kerbel,et al.  Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. , 1996, Journal of the National Cancer Institute.

[17]  G. Parmigiani,et al.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Wilson,et al.  Chemoresistance in solid tumours. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[20]  N. Aronson,et al.  Chemotherapy sensitivity and resistance assays: a systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Helmrich,et al.  Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo , 2005, Oncogene.

[22]  F. D. D. Fagagna,et al.  SASPense and DDRama in cancer and ageing , 2009, Nature Cell Biology.

[23]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[24]  Michael R. Green,et al.  Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.

[25]  A J Davis,et al.  Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. , 2000, The Lancet. Oncology.

[26]  P. Nelson,et al.  The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. , 2006, Cancer research.

[27]  Soyoung Lee,et al.  Chemotherapy response and resistance. , 2003, Current opinion in genetics & development.

[28]  J. Campisi,et al.  Secretion of Vascular Endothelial Growth Factor by Primary Human Fibroblasts at Senescence* , 2006, Journal of Biological Chemistry.

[29]  Bert Vogelstein,et al.  Cell-cycle arrest versus cell death in cancer therapy , 1997, Nature Medicine.

[30]  C. Higano,et al.  Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. , 2006, Urologic oncology.

[31]  D. Peeper,et al.  Senescence-messaging secretome: SMS-ing cellular stress , 2009, Nature Reviews Cancer.

[32]  W. Dalton,et al.  The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.

[33]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[34]  S. Weiss,et al.  A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells , 2006, Nature Cell Biology.

[35]  T. Wilson,et al.  Resistance mechanisms to cancer chemotherapy. , 2008, Frontiers in bioscience : a journal and virtual library.

[36]  M. Green,et al.  Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. , 1992, Cancer research.

[37]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[38]  C. Harris,et al.  WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. , 2009, Cancer research.

[39]  Xiaowo Wang,et al.  Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. , 2011, Genes & development.

[40]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[41]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[42]  S. Miyamoto,et al.  Calcium-Dependent Regulation of NEMO Nuclear Export in Response to Genotoxic Stimuli , 2006, Molecular and Cellular Biology.

[43]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[44]  S. Lowe,et al.  Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.

[45]  R. Kerbel,et al.  Molecular and Physiologic Mechanisms of Drug Resistance in Cancer: An Overview , 2004, Cancer and Metastasis Reviews.